France Analysis

Pages

Industry Trend Analysis - Macron's Focus On ONDAM To Continue To Challenge Drugmakers - AUG 2017

France's pharmaceuticals and healthcare market will benefit from an uptick in economic growth over Macron's presidential term, supported by a pro-business agenda and lower corporation tax. That said, with public debt ballooning to over 97.0% of GDP at the end of 2016, the French government will have to consolidate its budget. Over the long term, cost-containment will remain high on the governme...

READ FULL ARTICLE

Industry Trend Analysis - Sanofi/WRAIR Deal Heightens Argument Around US Investment - JULY 2017

The ongoing debate around the Zika vaccine deal between the US Army and Sanofi is set to continue throughout the R&D process. There is little interest for pharmaceutical companies to spend a large amount of money on developing a novel vaccine and there is risk to these not being profitable. If there are changes in the future licensing deals, due to ongoing controversy, this will...

READ FULL ARTICLE

Pages